Evidence map›Paper›PMID 23284626›Full record

ArticlePloS one2012

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.

Liliana B Menalled, Andrea E Kudwa, Sam Miller, Jon Fitzpatrick, Judy Watson-Johnson, Nicole Keating, Melinda Ruiz, Richard Mushlin, William Alosio, Kristi McConnell and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04826692 ("Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"), which is not on this map. Cited by 271 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04826692 phase3completednot on this mapstarted 2022, after this paper: background citation

"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"

TypeinterventionalSponsorInstituto de Investigacion Sanitaria La FeRan2022 to 2025Enrolled60ConditionsHuntington DiseaseArmsMetformin, Placebo
3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 1 synthesis or guideline pooled it, 520 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Targeting the cGAS-STING pathway mitigates Huntington disease pathogenesis in a knock-in mouse model.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. In Vivo PET Imaging of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  11. Article
  12. Article
  13. Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Preclinical evaluation of [Journal of molecular medicine (Berlin, Germany) · 2025
    Article
  18. Article
  19. Animal models of Huntington's disease. Pros and cons.Brain, behavior, & immunity - health · 2025
    Review
  20. Article

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Liliana B MenalledPsychoGenics Inc., Tarrytown, New York, United States of America.
Andrea E Kudwa
Sam Miller
Jon Fitzpatrick
Judy Watson-Johnson
Nicole Keating
Melinda Ruiz
Richard Mushlin
William Alosio
Kristi McConnell
David Connor
Carol Murphy
Steve Oakeshott
Mei Kwan
Jose Beltran
Afshin Ghavami
Dani Brunner
Larry C Park
Sylvie Ramboz
David Howland
Psychogenics (United States) · USCHDI Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor, cognitive and psychiatric manifestations. Since the mutation responsible for the disease was identified as an unstable expansion of CAG repeats in the gene encoding the huntingtin protein in 1993, numerous mouse models of HD have been generated to study disease pathogenesis and evaluate potential therapeutic approaches. Of these, knock-in models best mimic the human condition from a genetic perspective since they express the mutation in the appropriate genetic and protein context. Behaviorally, however, while some abnormal phenotypes have been detected in knock-in mouse models, a model with an earlier and more robust phenotype than the existing models is required. We describe here for the first time a new mouse line, the zQ175 knock-in mouse, derived from a spontaneous expansion of the CAG copy number in our CAG 140 knock-in colony [1]. Given the inverse relationship typically observed between age of HD onset and length of CAG repeat, since this new mouse line carries a significantly higher CAG repeat length it was expected to be more significantly impaired than the parent line. Using a battery of behavioral tests we evaluated both heterozygous and homozygous zQ175 mice. Homozygous mice showed motor and grip strength abnormalities with an early onset (8 and 4 weeks of age, respectively), which were followed by deficits in rotarod and climbing activity at 30 weeks of age and by cognitive deficits at around 1 year of age. Of particular interest for translational work, we also found clear behavioral deficits in heterozygous mice from around 4.5 months of age, especially in the dark phase of the diurnal cycle. Decreased body weight was observed in both heterozygotes and homozygotes, along with significantly reduced survival in the homozygotes. In addition, we detected an early and significant decrease of striatal gene markers from 12 weeks of age. These data suggest that the zQ175 knock-in line could be a suitable model for the evaluation of therapeutic approaches and early events in the pathogenesis of HD.

Indexed as

Behavior, AnimalDisease Models, AnimalGene Knock-In TechniquesAnimalsBody WeightCognitionDarknessFemaleGenetic MarkersHand StrengthHeterozygoteHomozygoteHuntington DiseaseMaleMiceNeostriatumGenetic MarkersNerve Tissue ProteinsRNA, Messenger

Identifiers

PMID23284626
PMCPMC3527464
OpenAlexW2048323087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.